|
|
1)
|
chain |
E |
residue |
21 |
type |
|
ligand |
|
sequence |
G
|
description |
binding site for residue 95G E 401
|
source |
: AC5
|
|
2)
|
chain |
E |
residue |
24 |
type |
|
ligand |
|
sequence |
A
|
description |
binding site for residue 95G E 401
|
source |
: AC5
|
|
3)
|
chain |
E |
residue |
26 |
type |
|
ligand |
|
sequence |
G
|
description |
binding site for residue 95G E 401
|
source |
: AC5
|
|
4)
|
chain |
E |
residue |
27 |
type |
|
ligand |
|
sequence |
T
|
description |
binding site for residue 95G E 401
|
source |
: AC5
|
|
5)
|
chain |
E |
residue |
28 |
type |
|
ligand |
|
sequence |
G
|
description |
binding site for residue 95G E 401
|
source |
: AC5
|
|
6)
|
chain |
E |
residue |
29 |
type |
|
ligand |
|
sequence |
E
|
description |
binding site for residue 95G E 401
|
source |
: AC5
|
|
7)
|
chain |
E |
residue |
30 |
type |
|
ligand |
|
sequence |
L
|
description |
binding site for residue 95G E 401
|
source |
: AC5
|
|
8)
|
chain |
E |
residue |
31 |
type |
|
ligand |
|
sequence |
T
|
description |
binding site for residue 95G E 401
|
source |
: AC5
|
|
9)
|
chain |
E |
residue |
34 |
type |
|
ligand |
|
sequence |
L
|
description |
binding site for residue 95G E 401
|
source |
: AC5
|
|
10)
|
chain |
E |
residue |
161 |
type |
|
ligand |
|
sequence |
A
|
description |
binding site for residue 95G E 401
|
source |
: AC5
|
|
11)
|
chain |
E |
residue |
175 |
type |
|
ligand |
|
sequence |
L
|
description |
binding site for residue 95G E 401
|
source |
: AC5
|
|
12)
|
chain |
E |
residue |
177 |
type |
|
ligand |
|
sequence |
M
|
description |
binding site for residue 95G E 401
|
source |
: AC5
|
|
13)
|
chain |
E |
residue |
27 |
type |
|
ligand |
|
sequence |
T
|
description |
binding site for residue 95G G 401
|
source |
: AC7
|
|
14)
|
chain |
E |
residue |
16-18 |
type |
binding |
ligand |
95G: N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide |
sequence |
FVM
|
description |
N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide binding site
|
source |
pdb_hetatom : 95G_5q01_E_401
|
|
15)
|
chain |
E |
residue |
20-22 |
type |
binding |
ligand |
95G: N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide |
sequence |
EGR
|
description |
N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide binding site
|
source |
pdb_hetatom : 95G_5q01_E_401
|
|
16)
|
chain |
E |
residue |
24-31 |
type |
binding |
ligand |
95G: N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide |
sequence |
ARGTGELT
|
description |
N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide binding site
|
source |
pdb_hetatom : 95G_5q01_E_401
|
|
17)
|
chain |
E |
residue |
34 |
type |
binding |
ligand |
95G: N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide |
sequence |
L
|
description |
N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide binding site
|
source |
pdb_hetatom : 95G_5q01_E_401
|
|
18)
|
chain |
E |
residue |
113 |
type |
binding |
ligand |
95G: N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide |
sequence |
Y
|
description |
N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide binding site
|
source |
pdb_hetatom : 95G_5q01_E_401
|
|
19)
|
chain |
E |
residue |
160-161 |
type |
binding |
ligand |
95G: N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide |
sequence |
VA
|
description |
N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide binding site
|
source |
pdb_hetatom : 95G_5q01_E_401
|
|
20)
|
chain |
E |
residue |
175-177 |
type |
binding |
ligand |
95G: N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide |
sequence |
LAM
|
description |
N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide binding site
|
source |
pdb_hetatom : 95G_5q01_E_401
|
|
21)
|
chain |
E |
residue |
27-28 |
type |
binding |
ligand |
95G: N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide |
sequence |
TG
|
description |
N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide binding site
|
source |
pdb_hetatom : 95G_5q01_G_401
|
|
22)
|
chain |
E |
residue |
31-32 |
type |
binding |
ligand |
95G: N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide |
sequence |
TQ
|
description |
N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-4-[(3,4-dichloro-1-methyl-1H-pyrazol-5-yl)oxy]benzene-1-sulfonamide binding site
|
source |
pdb_hetatom : 95G_5q01_G_401
|
|